Exosome Diagnostic and Therapeutic Market growing at a CAGR of 29.4% from 2021 to 2030.

January 30, 2025 03:44 PM AEDT | By EIN Presswire
 Exosome Diagnostic and Therapeutic Market growing at a CAGR of 29.4% from 2021 to 2030.
Image source: EIN Presswire
PORTLAND, IA, UNITED STATES, January 30, 2025 /EINPresswire.com/ -- Alarming rise in prevalence of cancer & infectious disease and increase in number of approval for exosome therapeutics & diagnostics are expected to notably contribute toward the growth of the global exosome diagnostic & therapeutic market during the forecast period.

Allied Market Research published a report, titled, "Exosome Diagnostic and Therapeutic Market by Application (Diagnostic, Therapeutic), by Product (Instrument, Reagent, and Software) by End User (Cancer Institute, Hospital, Diagnostic Center, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030." According to the report, the global exosome diagnostic and therapeutic industry was estimated at $224.34 million in 2020, and is anticipated to hit $2.9 billion by 2030, registering a CAGR of 29.4% from 2021 to 2030.

Download Sample PDF at: https://www.alliedmarketresearch.com/request-sample/1723

Key Takeaways:

The diagnostic segment to dominate by 2030

The instrument segment to maintain the lion’s share

Pharmaceutical and biopharmaceutical sector across the province. Asia-Pacific, however, would grow at the fastest CAGR of 30.3% by 2030.

Increase in use of multifunctional property of exosome therapy for chronic heart failure, Alzheimer's disease, Parkinson's disease, and cancer drive the growth of the global exosome diagnostic and therapeutic market. On the other hand, rise in demand for drug therapies and surge in R&D activities in the pharmaceutical and biopharmaceutical fields supplement the market growth even more. Moreover, surge in potential application of exosomes in cancer diagnosis and development of translational precision medicines are expected to create lucrative opportunities in the industry.

Major factors that boost the global exosome diagnostic and therapeutic market growth include increase in incidence of cancer, chronic, and infectious disease; growth in investments in R&D activities in exosome diagnostic and therapeutic industry; and surge in initiatives implemented by the government and non-government associations for healthcare development. In addition, technological advancements for easy exosome isolation and advancement in applications of exosome support the growth of the exosome diagnostic and therapeutic industry. In addition, the developing countries, such as China and India are expected to provide huge growth opportunities to the market. However, stringent government regulations for the approval of exosome diagnostic and therapeutic products and ack of awareness about the applications of exosome in developing countries restrict the market growth. The exosome diagnostic and therapeutic market analysis is segmented on the basis of application, product, end user, and region.

On the basis of application, it is divided into diagnostic application and therapeutic application. Increase in demand for exosome as a biomarker in the diagnosis of cancer, surge in prevalence of cancer with rise in geriatric population, and growth in sedentary lifestyle are the major factors that contribute toward the growth of the exosome diagnostic market, and exosome therapeutic market.

Market Segmentation:

By Application:

Diagnostic
Therapeutic
By Product:

Instrument
Reagent
Software
By End User:

Cancer Institute
Hospital
Diagnostic Center
Others
By Region:

North America (U.S., Canada, Mexico)
Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
Asia-Pacific (Japan, China, Rest of Asia-Pacific)
LAMEA (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Request for Customization: https://www.alliedmarketresearch.com/request-for-customization/1723

North America held the major share in 2020, generating nearly two-fifths of the global exosome diagnostic and therapeutic market, due to rise in product launches for exosome therapeutics, surge in the presence of key players, and development of R&D activities in the pharmaceutical and biopharmaceutical sector across the province. Asia-Pacific, however, would grow at the fastest CAGR of 30.3% by 2030. Increase in the prevalence of chronic and infectious disorders, growth in health care expenditures, and surge in demand for molecular diagnosis drive the market growth in the region.

Key players in the industry-

Exosome Diagnostics Inc.
NanoSomix Inc.
Thermo Fisher Scientific Inc.
Malvern Instruments Ltd.
System Biosciences Inc.
NX Pharmagen
Aethlon Medical, Inc.
Sistemic Inc.

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Market Research
+ 1 800-792-5285
email us here
Visit us on social media:
Facebook
X
LinkedIn
YouTube

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.